Protocol Ledger

NCT03443869 · Phase III · COMPLETED

Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)

Interventional Phase III clinical trial protocol NCT03443869 sponsored by Merck & Co. in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-05-03 Enrollment: 601 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03443869
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)601 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03443869
Protocol FieldVerified Registry Value
NCT IdentifierNCT03443869
Consolidated Lead SponsorMerck & Co.
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment601 participants (ACTUAL)
Registered Start Date2018-05-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI